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ABSTRACT 
 
 
Type 1 diabetes mellitus (T1DM) is caused by an autoimmune destruction of islet β 
cells. Current treatments are based on replacement therapy using insulin analogs but, 
due to the impossibility to simulate physiological glucose control, it leads to diabetes 
complications. Thus, novel treatments are required. As a difference of what happens 
with the immunosuppressor therapy, which have limited clinical efficacy, the induction 
of antigen specific tolerance (AST) can specifically block the activation of autoreactive 
T cells, preserving the survival and function of the pancreatic β cells and preventing the 
development of T1DM. Here, two different strategies are followed, in order to induce a 
tolerogenic environment. The expression of the self-Ag  insulin under non-inflammatory 
conditions, using the SV40 background allows the restoration of the AST in the 
RIPB7.1 mouse model. Also, the protective role in pancreatic islets of the liver receptor 
homologue 1 (LRH1) against apoptosis was considered, as well as the prevention of 
hyperglycemia in T1DM mouse models by the induction of an anti-inflammatory 
environment promoted by the LRH1 agonist BL001. However, the limitations of BL001 
as potential medication prompted us to develop an in vitro drug-screening platform that 
allowed the identification of two novel LRH1 agonists, BL002 and BL003. These non-
toxic agonists protect mouse islets from cytokines-induced apoptosis, improving their 
survival. Thus, the AST induced by SV40 vector as well as the new generation of LRH1 
agonists BL002 and BL003 must be considered as two promising therapies for the 
treatment of T1DM 
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I. INTRODUCTION  
 
 
1. Autoimmune diseases 
 
1.1. The immune system in autoimmune diseases 
 
Autoimmune diseases (AD) are a group of disorders in which the immune cells react 
against the body’s own cells leading to a severe tissue damage with subsequent 
harmful effects for the subject. Some examples of major ADs include rheumatoid 
arthritis, in which the synovial cells of the joints are attacked 1, type 1 diabetes mellitus 
(T1DM) in which the insulin producing β cells are destroyed 2 or multiple sclerosis, in 
which the immune system reacts against oligodendrocytes, the cells protecting the 
axons of motor neurons 3. Although most of the mechanisms underlying tissue 
destruction are known, the etiology of these diseases remains unclear. Currently, the 
hypothesis mostly accepted establishes that patients suffering AD present a genetic 
predisposition that in combination with environmental factors favors the development of 
the autoimmune attack 4. At the cellular and molecular level, the immune system, 
responsible to defend us from foreign invaders, is the effector of the AD. The immune 
system establishes a delicate balance between inflammation (recognition of foreign) 
and tolerance (recognition of own) and the break of this tolerance is what triggers the 
AD.  
 
The immune response can be functionally divided into the innate and the adaptive 
responses. The innate response is the first line of defense. The cells of the innate 
immune system express cell surface receptors that directly recognize pathogens 
through pathogen associated molecular patterns (PAMPS) which are shared between 
the different groups of microorganisms (bacteria, viruses…). The strength of the innate 
response is the capacity to take immediate action since it is not specialized for specific 
pathogens. If this innate response is unsuccessful in destroying the pathogens, after 4 
to 7 days the adaptive immune response sets in, targeting the pathogens more 
accurately 5,6. This is based on the capacity of the adaptive response to precisely 
recognize specific pathogen structures known as antigens (Ags). These Ags need to be 
processed before being available to be recognized.  
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The knowledge obtained from the study of animal models of AD and the data collected 
from patients, suggests that among all the cells of the adaptive immune system the two 
main drivers of AD are the T and the B cells. Based on this, the AD can be classified in 
those triggered mainly by T cells and those triggered mainly by B cells, although 
eventually, both cell types are involved in all AD in some degree. Additionally, in animal 
models of AD the pathogenic symptoms of the disease can be triggered by only one of 
the two groups of T cells that can be distinguished by their surface markers as CD4+ or 
CD8+ T cells. In this thesis, we will focus in AD triggered by T cells.  
 
 
Figure 1. Antigens can be presented by MHC I or MHC II determining the class of 
lymphocytes activated. Schematic representation of the two modes of Ag processing. A. 
Endogenous pathway for presenting Ag from a host cell to CD8
+
 T cell by MHC I. B. Exogenous 
pathway presents the peptide products from an endocytosed Ag by an APC to a CD4
+
 T cell in 
the context of MHCII. Image taken from Bellanti, 2012 
8
.  
 
The T cells, through their surface molecule T cell receptor (TCR), can identify both 
foreign and self-Ags, when the Ags are loaded and presented by the major 
histocompatibility complex (MHC). There are two types of MHC, class I, which is 
expressed and present in the surface of all body cells, and class II, which is expressed 
only by antigen presenting cells (APCs) 7. Cells expressing class I MHC molecules 
present endogenous Ags that are recognized by one or very few clones of CD8+ T 
cytotoxic lymphocytes (CTL) (Figure 1). Thus, in an event of a viral infection, the 
infected cells process and express via class I MHC the viral Ags, which are recognized 
by the CTLs that then, are activated. These activated CTLs remove the affected cells 
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by releasing cytotoxic mediators. The Ags loaded in class II MHC molecules come from 
either pathogens or cell debris that have been phagocytosed by APCs. Mainly, 
dendritic cells and monocytes function as APCs. Also, the monocyte-differentiated cells 
(macrophages) such as Kupffer cells (located in the liver), Langerhans cells (located in 
the skin) or the glial cells (located in the nervous system) act as APCs. In this way, 
APCs are distributed all over the body. The Ags presented by class II MHC are 
recognized by the CD4+ T helper (Th) lymphocytes, which produce cytokines and 
stimulate B cells to generate/secrete antibodies.  
 
The key factor that determines a tolerance or an inflammation state is the way that Ags 
are presented and the maturation state of the APCs (Figure 2) 9,10. Under inflammatory 
conditions (Figure 2, left), immature APCs, which have a great phagocytic capacity, 
collect either pathogens or cell debris (produced by the inflammation and the action of 
the innate immune response) and then migrate to the lymph nodes where they mature 
(upregulate the expression of costimulatory molecules in their cell surface and secrete 
pro-inflammatory cytokines). Activation of CD4+ Th cells by activated APCs induces 
their differentiation into inflammatory T cells that migrate outside of the lymph nodes 7 
11–13. On the other hand, in the absence of inflammatory signals, immature APCs are 
able to capture and process Ags, and when these Ags are presented to T cells without 
the presence of costimulatory signals, they induce tolerance instead of inflammation 
(Figure 2, right).  
 
 
Figure 2. The maturation state of APCs induces tolerance or inflammation. The presence 
of pathogen or infected cells, as well as tissue necrosis favors the activation of the APCs, 
upregulating the expression of costimulatory surface markers and the secretion of 
proinflammatory cytokines. In the case of apoptotic cells or tissue healing, APCs induce a 
tolerogenic environment due to the lack of stimulatory signals.  
 
There are two mechanisms that preserve the homeostasis and the tolerance. By these 
mechanisms, those clones of T cells that react against the self-Ags, known as 
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autoreactive T cells are recognized and eliminated. During development, a genetic 
recombination process happening in the T progenitor cells, randomly generates a 
plethora of T CD4+ and CD8+ cell clones 14. By an exhaustive selection mechanism 
occurring in the thymus, known as clonal deletion, host’s self-Ags are presented by the 
thymic stromal cells and most of the T cell clones that recognize them with high affinity 
are depleted 15. This phenomenon is known as “central tolerance” 15–19. A secondary 
check point, mediated by APCs and known as “peripheral tolerance”, removes those 
autoreactive T cell clones that escaped from the central tolerance (Figure 3) 20. Three 
different ways account for peripheral tolerance: a) by anergy, in which the CD4+ cells 
becomes unresponsive after Ag presentation 11,12,21,22; b) by depletion, which consists 
in the elimination of autoreactive T cells by apoptosis after persistently encounter self-
Ags 23; and c) by suppression that is mediated by regulatory T cells (Tregs), which are 
specialized T cells that block the activation of the autoreactive T cells 24,25.  
 
Figure 3. Mechanisms of peripheral tolerance. Three different mechanisms have been 
established to eliminate autoreactive T cells: anergy, inducing a hyporesponsive state, 
suppression, due to the action of regulatory T cells; and deletion, inducing apoptosis after a 
long-term exposition to the Ag. Image taken from Abbas, 2007 
26
.  
 
The key question to understand the etiology of ADs is to know how and what breaks 
the tolerance in certain subjects. It has been postulated that in certain cases the 
similarity between pathogenic Ags and self-Ags (known as Ag mimicry) can trigger the 
autoimmune process 27. However, another layer of complexity resides in the fact that 
autoreactive T cells are found also in the healthy population that have encountered with 
same pathogenic Ags than AD patients, without manifesting the symptoms of the 
disease 28. This reveals the complexity of the problematic of AD.   
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1.2. Requirements of new treatments for autoimmune diseases  
Currently there is not a treatment able to restore the immune tolerance lost in AD 
patients. Therefore, ADs are not curable and only palliative therapies to treat the 
symptoms are available. Current treatments are classified into two categories: 1) 
symptomatic or replacement therapy and 2) immunosuppressive or immune-
modulation therapy.  
 
In many ADs the pathogenic symptoms are manifested when the target organ or target 
cells are mostly destroyed, and the remaining cells cannot support anymore the organ 
functions. For example, in T1DM patients the symptoms of the diabetes are manifested 
when the target cells (the pancreatic β cells, responsible for insulin secretion) are 
destroyed by around 90% 29. These patients will need insulin supplementation during 
their whole life to restore the normoglycemia. This palliative approach does not solve 
the problem since it does not stop the immune attack over the β cells, thus preventing 
their recovery.  
 
In other cases, when the replacement therapy is not possible such as in multiple 
sclerosis, the right approach is to induce immunosuppression, aiming at avoiding the 
activation of immune cells and thus reducing the inflammation 30. This therapeutic 
approach involves the suppression of the entire immune system by the use of 
compounds such as cyclophosphamide 31,32, which is cytotoxic to the lymphoid 
population 33, or glucocorticoids 34, which can alter gene expression in the host cells by 
inhibiting the production of proinflammatory cytokines and inducing apoptosis in a 
variety of immune cells, systemically decreasing the inflammation 35,36. A current view 
to treat ADs pretends to reduce the side effects of systemic immunosuppressors by 
targeting exclusively the pro-inflammatory cytokines and the T cells. One strategy that 
has been considered in this sense is the use of monoclonal antibodies 37–40. For 
example, the antibody anti-CD3, is able to block the activation of T cells through 
binding to their CD3 receptor 41 or anti-TNFα which is able to block the soluble pro-
inflammatory cytokine tumor necrosis factor α (TNFα). This cytokine has been found 
elevated in many ADs 42. Initially, 60–70% of autoimmune patients respond to this 
therapy, but only a small percentage of the patients present a long-lasting period of 
remission. 
 
The down side of using immunosuppressive drugs is that they increase the risk of 
infection by opportunistic organisms such as herpes or hepatitis, tumor development 
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due to the inability to stablish an immune response against malignant cells,  
cardiovascular diseases, attributed to the chronic inflammatory state as well as the 
hyperglycemic and hyperlipidaemic adverse effects 43–45. Some novel small molecules 
that target particular proteins are being developed with the aim to increase the 
specificity of the anti-inflammatory therapy. This seems to be a good approach as it 
pretends to avoid general immunosuppression, but unexpectedly current molecules still 
do not increase significantly the remission rate despite the significant advances in last 
few decades. Hence, the ideal intervention for the treatment of ADs should be able to 
specifically remove the autoreactive T cell clones, without altering/damaging the rest of 
the immune cells thus avoiding the adverse secondary effects.  
 
 
2. Type 1 diabetes mellitus as an autoimmune disease  
 
2.1. Diabetes mellitus and glucose homeostasis 
Diabetes mellitus (DM) is defined as a group of metabolic disorders characterized by 
the inability of the organism to maintain the homeostasis of blood glucose leading to 
hyperglycemia. The control of the blood glucose levels (glycaemia) relies in the 
pancreas.  
This organ can be functionally divided into the exocrine pancreas, involved in digestive 
functions, and the endocrine pancreas, known as the islets of Langerhans or 
pancreatic islets, which regulates glucose homeostasis (Figure 4). The exocrine 
pancreas represents around 96% of the total pancreatic mass, while the endocrine 
pancreas constitutes the remaining 4% approximately 46. Pancreatic islets are spherical 
clusters of cells scattered throughout the exocrine pancreas and in close proximity to 
fenestrated capillaries for the release of hormones into the bloodstream 47,48. The most 
abundant cell types of the pancreatic islets are the insulin-producing β cells and the 
glucagon-producing α cells, however their proportion and distribution within the islets 
vary among species. In the case of human islets, β cells account for approximately 
60% of the islet cells and appear to be randomly distributed throughout the islet and α 
cells represent approximately the 30%. The other cell types are: somatostatin-
producing δ cells (~8%), ghrelin-producing ε cells (~1%) and pancreatic-polypeptide 
producing PP cells (0,3%) 49,50. In the case of murine islets, the β cells represent 
approximately 80% of the islet cells and are located in the central core of the islet, 
surrounded by the α cells that account for 15-20% of islet cells. The other islet cell 
types include δ cells (less than 10%) and PP cells (less than 1%). ε cells are only 
present during embryonic development 51.   
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Figure 4. Endocrine and exocrine compartments of the pancreas. Almost all of the 
pancreas (~96%) consists of exocrine tissue that produces pancreatic enzymes for digestion. 
The endocrine pancreas or islets of Langerhans are clusters of 5 different types of cells (β, α, δ, 
PP and ε cells) that form spherical structures embedded in the exocrine pancreas. 
 
Insulin and glucagon are the two main hormones involved in the glucose homeostasis 
(Figure 5). Upon increased blood glucose, β cells are stimulated and secrete insulin, 
which is the hormone that enhances the uptake of glucose by insulin target tissues, 
(liver, skeletal muscle and adipose tissue) decreasing the levels of glucose in the 
blood. In addition, insulin also suppresses the production of glucose by the liver 52. As a 
counterpart, during a hypoglycemic status, α cells are stimulated and secrete glucagon 
that increases glucose release by the liver restoring the normal blood glucose levels 53–
55.  
 
Figure 5. Regulation of glucose homeostasis by the endocrine pancreas. Based on blood 
glucose levels, 2 different scenarios are observed: high levels (blue arrows) and low levels 
(orange arrows). These conditions stimulate different pancreatic cell types to produce: insulin 
during hyperglycemic conditions or glucagon in hypoglycemic states. These hormones are 
secreted to the blood stream and act on their target tissues to regulate the glucose levels.   
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The insulin gene encodes a 110 aminoacid precursor, known as preproinsulin, which 
has a signal peptide (24 amino acids), a B-chain (30 residues), a connecting peptide 
(C-peptide) (35 residues), and an A-chain (21 aminoacids) (Figure 6). The signal 
peptide, which directs the protein to the lumen of the endoplasmic reticulum (ER), is 
cleaved to form the proinsulin that is then translocated to the Golgi 56,57. The proinsulin 
is processed by the β cells specific enzymes convertases PC1 and PC2 and 
carboxypeptidase, specifically expressed in the β cells, producing the active two-chain 
mature insulin and free C-peptide (Figure 5). This proteolysis is initiated within the cis-
Golgi and completed in the secretory vesicles, which derive from the trans-Golgi 58–65. 
Insulin, together with the C-peptide, is stored in the secretory granules awaiting release 
on demand. Insulin is secreted primarily in response to glucose, which enters into β 
cells through the glucose transporter 2 (GLUT2). Within the β cell, glucose is 
metabolized increasing the levels of adenosine triphosphate (ATP), a signalling 
molecule needed for insulin release, and to close the ATP‐sensitive K+ channels. The 
closure of these channels causes the membrane depolarization, which allows the Ca2+ 
influx and thus the elevation of cytosolic Ca2+ concentration. This elevation rapidly 
increases the rate of insulin exocytosis by the fusion of the secretory granules with the 
plasma membrane 66,67. 
 
 
 
Figure 6. Schematic representation of human preproinsulin structure and its processing 
until biologically active insulin. Preproinsulin (A) contains four regions: signal peptide (blue), 
B chain (orange), C-peptide (magenta) and A chain (green). This protein is processed in ER 
and Golgi, producing the mature insulin (B). Image obtained from Matteucci 2015 
68
.  
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Alterations in insulin production and/or secretion lead to the dysregulation of glucose 
homeostasis with the subsequent development of hyperglycaemia and DM. Blood 
glucose dysregulation suffered by diabetic patients is associated with long-term 
damage, dysfunction and failure of different organs, especially eyes, kidneys, nerves, 
heart, and blood vessels 2. According to the last edition of the International Diabetes 
Federation Atlas published in 2017, 425 million people suffer diabetes and it is 
expected to rise to 592 million by 2035, reaching worldwide pandemic magnitudes69. 
Thus, DM is defined as a group of metabolic disorders, characterized by hyperglycemia 
due to defects in insulin secretion, insulin action or both 2. Depending on its etiology, 
DM has been classified into 3 main forms: T1DM, due to autoimmune destruction of the 
insulin producing β cells; type 2 diabetes mellitus (T2DM), caused by insulin resistance 
in its target tissues and a progressive loss of insulin secretion due to the exhaustion of 
the β cells; and gestational diabetes mellitus (GDM) diagnosed during pregnancy 2. 
There are other types of diabetes, much less common, which include those caused by 
genetic defects of β cell function.  
 
Depending on the etiology of the diabetes different therapeutic approaches are used. In 
the case of T2DM, normally associated with obesity, the first approach includes 
changes in life style, such as healthy diet and physical activity, and oral medications 
such as metformin, which reduces the hepatic glucose production70 not requiring, 
initially, treatment with exogenous insulin. However, insulin administration can be 
necessary for these patients at long-term due to the progression of the disease. On the 
other hand, T1DM patients need the administration of recombinant insulin from the 
moment of the diagnosis of the disease.  
 
2.2. Type 1 diabetes mellitus  
T1DM, also known as juvenile diabetes or insulin-dependent diabetes, is an AD 
predominantly diagnosed in children and young adults. T1DM is one of the most 
prevalent chronic illnesses diagnosed in these ages. In 2017, more than one million 
children and adolescents suffer this disease and each year around 130.000 new cases 
are diagnosed69. The increasing incidence is even higher than expected in children 
from 0 to 14 years. This is an alarming scenario, even more when the reason of the 
increase is unknown71. As previously indicated, T1DM is a chronic disease 
characterized by insulin deficiency and hyperglycemia due to the autoimmune 
destruction of the insulin producing β cells2. This T cell-mediated AD progresses 
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sequentially and begins prior to the symptomatic phase, when the patients lack β cells 
(around 90% loss), becoming insulin dependent 29.  
 
The causing factor of T1DM is still unknown, but both genetic and environmental 
factors interact to trigger for the disease. The risk for T1DM in siblings of patients is 15-
fold higher than in the general population, suggesting that genetic factors play an 
important role in disease susceptibility72. Linkage and association studies have 
identified several loci as T1DM susceptibility regions. One of them is the human 
leukocyte antigen (HLA) class II region (about 50% of genetic T1DM risk73) localized at 
chromosome 6p21, which contains genes involved in innate and adaptive immune 
functions 74,75. The remaining loci correspond to several (close to 50) non-HLA loci. 
However, the fact that the monozygotic concordance rate is 50% demonstrates that 
environmental factors must play an important role 72. Some proposed initiation factors 
are viral infections particularly the enteroviruses (for example, coxsackievirus), which 
can produce some islet injury and activate the diabetogenic response76–78.   
As explained above, in many ADs the symptoms appear only when the affected organs 
are severely damaged, as this is the case of T1DM. In the onset of T1DM the damage 
to the β cells is too high and thus exogenous insulin administration is absolutely 
required to maintain the normoglycaemia. Therefore, the identification of markers that 
would allow the diagnosis of the disease at an asymptomatic stage becomes a priority.  
Also this will be of help to increase our understanding of the disease progression in 
order to prevent complications such as diabetic ketoacidosis (DKA) at the diagnosis, 
and even to prevent the development of diabetes. In T1DM patients it has been 
identified antibodies that react against self-proteins such as antibodies against insulin, 
the major T1DM autoantigen79–82, the glutamate decarboxylase (GAD65)83,84, IA-2A 
(ICA512)85, and ZnT886. These antibodies can be easily measured and quantified from 
serum samples. They appear before the onset of diabetes and therefore could be used 
as T1DM markers. It has been proposed that the risk of developing hyperglycemia 
could be quantified through the determination of these biomarkers 87,88. Also, their 
detection in relatives of T1DM patients together with the HLA genotype could predict 
the risk for developing the disease 89, increasing the possibilities proportionally with the 
number of different autoantibodies90,91.  
 
Based on the presence of autoantibodies, the progression of T1DM has been divided in 
three stages. Stages 1 and 2, during the presymptomatic phase of the disease, are 
defined by the presence of 2 or more islet autoantibodies (stage 1) and development of 
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glucose intolerance (stage 2). The 3rd stage, during the symptomatic phase, occurs 
with the development of hyperglycemia due to the β cell mass reduction. This last 
stage is accompanied by polyphagia, polyuria, polydipsia, weight lost and DKA (Figure 
7) 2,92,93.  
 
Figure 7. Different stages of T1DM progression. According to the development of symptoms, 
T1DM can be divided in presymptomatic and symptomatic phases. But also, and considering 
the markers, 3 main stages can be stablished. Those individuals with genetic and environmental 
risk can be initiated with the appearance of islet autoantibodies (during the presymptomatic 
phase) (stage 1). If the disease progresses, glucose intolerance appears (stage 2) reaching the 
symptomatic phase with the appearance of hyperglycemia when the β cell mass decreases until 
around 10% (stage 3).  
 
 
2.3. Mechanism of immune attack in type 1 diabetes mellitus 
The implication of the immune system in the development of T1DM was demonstrated 
by the use of cyclosporine (an immunosuppressor that decreases the production of 
pro-inflammatory cytokines by the T cells) that improves β cell survival94. However, as 
with basically all ADs, the etiology of the T1DM remains unknown. 
 
T1DM begins with the loss of the self-tolerance to the β cell self-Ags that usually occurs 
early in life and can be triggered by a viral infection in the pancreas (Figure 8)95. These 
insults induce an initial damage of the β cells, which causes the release of self-Ags and 
pro-inflammatory cytokines. The APCs present within the pancreas uptake the released 
β cell Ags and migrate to the draining lymph nodes (LN), where they activate islet-
specific CD4+ and CD8+ T cells96. Activated islet-specific T cells migrate to the 
pancreas thereby enhancing the inflammation and the insulitis97. The CD4+ T cells 
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secrete pro-inflammatory cytokines, mainly interferon γ (IFNγ), and chemokines, 
resulting in the recruitment of more immune cells98,99. The released IFNγ increases the 
activation of APCs and enhances the production of pro-inflammatory cytokines, 
including interleukin-1β (IL-1β) and TNFα. Since β cells express high levels of IL-1 
receptor this makes them more sensitive to the IL-1β released by APCs. IFNγ, IL-1β 
and TNFα also induce the expression of reactive oxygen species (ROS) including nitric 
oxide by β cells, which induces cell damage and apoptosis95,100. Apart from the APCs, 
CD4+ T cells can also activate the CD8+ T cells. Then, they migrate to the pancreas 
and the recognition of the Ag presented by the MHC class I from the β cells induces the 
secretion of granzymes and perforin with the subsequent cell death101. Interestingly, a 
reduced suppression capacity of Tregs can also participate in the activation of 
autoreactive T cells102. 
 
In a second stage, the immune attack against β cells is worsening. At the beginning, 
only few Ags are targeted by autoreactive T cells, however as a consequence of this 
initial β cell death together with the progression of insulitis, more and new Ags are 
released. This process is known as epitope spreading, that increasing the strength of 
the disease with the activation and recruitment of other autoreactive T cell clones 
specific to the new Ags103,104. Thus, the immune scenario is aggravated during the 
progression of T1DM. 
 
 
Figure 8. The immune components involved in the process that leads to β-cell 
destruction in T1DM. An initial β cell damage caused by pathogens such as virus can induce 
the secretion of proinflammatory cytokines as well as β cell Ags. This can trigger the maturation 
of the APCs that migrate to the pancreatic lymph nodes. There, these mature APCs activate the 
autoreactive CD4
+
 and CD8
+
 T cells which migrate to the pancreatic islets and promote the β 
cell death through the secretion of proinflammatory cytokines as well as granzimes and perforin.  
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2.4. Preclinical models to study type 1 diabetes mellitus in the laboratory 
One approach to elucidate the etiology and the development of T1DM is the use of 
animal models. Mouse models are useful to study and understand the molecular bases 
of the β cell destruction, and to assay the effect of novel therapeutic agents. Here we 
briefly describe the most used mouse models to study T1DM:  
 
 Spontaneous model: non-obese diabetic (NOD) mice 
The NOD mouse is the most used model for T1DM studies since it shares several 
similarities with the human disease105 such as structural analogies of class II MHC 
which can be responsible of the immune attack against β cells106. These varieties of 
class II MHC can cause T1DM susceptibility, producing a spontaneous infiltration that 
destroys the pancreatic β cells107. This infiltration is predominantly composed of CD4+ 
and CD8+ lymphocytes, macrophages, B cells and NK cells, mimicking the infiltration 
happening in human islets108,109. T1DM onset appears between 10 to 14 weeks of age, 
when approximately 90% of pancreatic β cells are destroyed. The incidence of 
hyperglycemia is higher in females with values that range between 60 to 80%, while in 
males is between 10 to 30%110. Despite that NOD mouse can be the T1DM model that 
better resembles the human disease, the onset of the disease cannot be accurately 
predicted, thus programming experiments becomes challenging. This is an important 
fact when it comes to test therapeutics agents.  
 
 Drug-inducible model: streptozotocin administration 
The administration of streptozotocin (STZ) specifically induces β cell death since this 
compound enters through the GLUT2 transporter111.This model provides a simple, low-
cost and easily controllable approach to induce hyperglycemia112. The protocol to 
induce T1DM employs multiple administrations of low-dose STZ which produce an 
initial β cell damage that triggers an inﬂammatory process causing the further loss of β 
cells that results in insulin deﬁciency and hyperglycaemia, mimicking human T1DM. 
Thus, low doses of STZ to mice for 5 consecutive days activate the immune attack 
against β cells. Two weeks after the first administration of STZ around a 40% of mice 
become hyperglycemic113. This model is appropriated for studying the pathological 
consequences of T1DM, but also to assess and evaluate experimental approaches for 
the treatment of this disease. The disadvantage of this model is that the use of these 
chemicals, despite their high specificity to β cells, can produce some toxicity in other 
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organs113,114. Hence, although the STZ administration to mice can be used as a T1DM 
model, it is not the best model to mimic this disease.  
 
 Pathogen-induced model: RIP-LCMV mice   
Some viruses, such as enteroviruses or rotaviruses, have been suggested to be 
associate with mediators of T1DM, based on the detection of enteroviral RNA in the 
sera of T1DM patients115,116, and the increased levels of anti-rotaviruses antibodies that 
have been related to the appearance of β cell autoantibodies in children with T1DM 
risk117–119. Viral infections can induce direct β cell lysis, bystander activation of 
autoreactive T cells, loss of Tregs cells or molecular mimicry. Thus, several animal 
models use viruses to induce the β cell destruction120. An example is the RIP-LCMV 
mouse in which a defined viral Ag of the Lymphocytic Choriomeningitis Virus (LCMV) is 
expressed in β cells by the use of rat insulin promoter (RIP)121. This model is based on 
breaking the tolerance to a defined target autoantigen expressed by β cells through a 
viral infection. Thus, the infection of the mice with the LCMV activates the immune 
system against the viral Ags, which are also presented specifically in β cells. This 
induces the selective removal of β cells with an incidence of 90%121. However, because 
this model depends on the replication level of the virus and the timing of the infection 
the results obtained experience high variations.  
 
 DNA-inducible model: RIPB7.1 mouse model 
The RIPB7.1 is a transgenic model of experimental autoimmune diabetes (EAD) that 
presents a rapid development of diabetes after antigenic challenge with insulin. The 
RIPB7.1 mice express the T cell costimulatory molecule B7.1 (CD80) under the control 
of RIP, thus as before, only β cells express B7.1. Mice are immunized intramuscularly 
with a plasmid expressing the mouse preproinsulin II, that acts as the autoantigen that 
induces a selective T cell mediated immune response against the pancreatic β cells122. 
After the preproinsulin administration, 60 to 95% of these animals develop 
hyperglycemia within 3 to 5 weeks without gender deviation. The non-immunized 
animals do not develop EAD spontaneously. The presence of the costimulatory 
molecule B7.1 does not trigger the immune attack against β cells but it is necessary for 
the T cell effector function with the subsequent development of EAD123.  
 
This model presents some advantages. Due to the absence of gender deviation, entire 
litters can be used for experimentation, and, considering that only one allele of the B7.1 
transgene is sufficient for the EAD development, the crossing with other transgenic 
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mice is possible without detrimental effects. The use of plasmid DNA to trigger the 
immune attack provides a better control of the induction of the disease obtaining more 
consistent results. This model shares some features with human T1DM: it is 
characterized by CD4+ and CD8+ insulitis that leads to β cell damage and insulin 
deficiency. The RIPB7.1 mice are suitable to evaluate therapeutic interventions based 
on the prevention of the autoimmune attack as well as to study mechanisms of insulin-
specific T cell reactivity122,123.  
 
3. Treatments for type 1 diabetes mellitus   
 
The actual treatment for T1DM patients is the administration of exogenous insulin or 
insulin analogues. Most patients are diagnosed when the lost of β cells is very 
significant and the pancreas cannot regulate the blood glucose levels. Patients must 
tightly and constantly control the glycaemia with glucometers and administer 
recombinant insulin their selves. A slight fail in glucose determination or insulin 
administration cause severe consequences due to the impossibility to simulate 
physiological glucose control and producing high variations of glycaemia. Thus, severe 
complications of diabetes cannot be avoided in most of cases. Insulin administration is 
a palliative treatment that does not avoid the development of life-threatening 
complications, and new therapies are needed.  
 
3.1. Experimental therapies  
 
3.1.1. Immunosuppression therapies 
 
Immunosuppression consists in the removal or inactivation of self-reactive immune 
cells and the neutralization of the secreted pro-inflammatory cytokines. In T1DM 
patients, the use of monoclonal antibodies as anti-CD3 antibodies has been partially 
successful. The administration of anti-CD3 in T1DM patients showed a decreased 
demand for exogenous insulin together with an increased of endogenous production of 
insulin. However, the disease amelioration was short, even lower than two years41,124–
128. Also, a reduction in the doses to decrease the undesired side-effects of 
immunosuppression, such as the reactivation of Epstein Barr virus, eliminated the 
benefits of this treatment44. Therefore, since T1DM is a T cell-mediated disease, other 
strategies such as the use of the antibodies Abatacept (anti-CTLA) or Alefacept (anti-
CD2), have tried to target specifically the activation of these immune cells with only 
slight reduction on insulin requirements129,130. Other antibodies (Canakinumab – anti-IL-
1β) or small molecules (Anakinra - IL-1β receptor antagonist) have been used to 
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neutralize the pro-inflammatory cytokines IL-1β. However, these treatments did not 
improve the levels of the C-peptide131. 
Therefore, the non-specific immunosuppression approaches can provide minimal 
benefits and a high risk of opportunistic infections.   
 
3.1.2. Induction of tolerance by self-antigen presentation 
As described above current treatments for AD are only palliative, since they do not 
target the root of the problem, and in addition entail risks associated to the treatment 
itself. Even without knowing what triggers T1DM, the activation of autoreactive T cells 
is the responsible of the tissue destruction. Therefore, the ideal therapeutic intervention 
to cure ADs will consist in the specific suppression of solely the autoreactive T cell 
clones that recognize the self-Ags. This process, known as antigen specific tolerance 
(AST) restoration, consists in the presentation of the implicated self-Ag to the 
autoreactive T cells in the absence of costimulatory molecules (CD40, CD80/86) and 
pro-inflammatory cytokines. In this scenario, instead of being activated, autoreactive T 
cells will become anergic or depleted, or they will become induced regulatory cells 
(iTregs) with suppressing capabilities. Therefore, the restoration of the AST will allow 
the specific blockage of the autoreactive T cells while maintaining the capacity of the 
immune system to clear non-self-Ags, protecting the organism from a pathogenic 
attack. 
 
The restoration of AST has shown beneficial effects in animal models of ADs inducing 
a long-lasting tolerance without side effects132–138, and in particular in T1DM139,140. In 
most of the cases, when the Ags are administered once the autoimmune attack has 
started, the AST has been only partially achieved. However, in other cases, mostly 
when the tolerogenic Ags were administered prophylactically (sometimes during the 
neonatal stage) the development of the inflammatory symptoms are avoided141–143. This 
is precisely one of the major limitations at the time of translating this therapeutic 
strategy into humans. Due to the absence of markers to detect the different stages of 
the AD, in most of the cases the intervention would be applied once that the 
autoimmune attack in ongoing, meaning that not only naïve but activated/memory T 
cells must be targeted, adding another layer of difficulty. Targeting activated/memory T 
cells increases the risk that the administration of the self-Ag involved in the AD can 
exacerbate the immune response instead of inducing tolerance. So far, the translation 
of AST into humans is challenging.  
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There are several factors such as the type of Ag and its nature, how is presented and 
the amount present that must be considered to achieve an efficient induction of AST. 
First, identify the major self-Ag. In the case of T1DM, insulin can be recognized as the 
major target of autoreactive T cells79,80,144–146. Also, the specific sequence of the Ag can 
also influence the outcome. Thus, different insulin isoforms have been tested to induce 
AST. For example, the administration of high doses of preproinsulin induced 
immunogenicity instead of tolerance122,147,148. However, the use of the non-secreted 
form, the proinsulin sequence, reduced the incidence of hyperglycemia149. Last, 
adequate levels of Ag expression in the proper cellular location are also important150. In 
the NOD mice, oral administration of 1 mg of insulin protected mice against the 
development of hyperglycemia while lower doses (0.01 to 0.1 mg) did not reach this 
protection151.  
 
AST has already been applied in clinical trials. For example, in T1DM patients 
vaccinated with a proinsulin encoding plasmid, C-peptide levels were preserved 
together with a reduction in proinsulin reactive CD8+ population and islet 
autoantibodies. However, in these patients insulin requirements were maintained 
indicating this treatment needs further improvements152,153.  
 
Considering the current state of AST intervention, it is necessary to define more 
consistent protocols to efficiently restore the broken tolerance in patients and, in the 
case of T1DM patients, reestablish glucose homeostasis. 
 
 
3.1.2.1. Organ targeting to induce antigen specific tolerance 
The selection of the target organ for the delivery of the self-Ags influences the way that 
the tolerance is induced. Oral or mucosal administration delays T1DM onset in murine 
models151,154,155. However, the human translational trials have shown that nasal or oral 
insulin administration provided limited clinical benefits156–161. A possible explanation 
could rely on the Ag dose used. Based on the weight of mice the effective dose in mice 
was 100 fold higher than the dose administered in humans.  
 
Alternatively, intramuscular administration allows an easy and efficient way to express 
the Ag in the host tissue. After intramuscular administration, the myocytes are the main 
target cells that express the Ag, although dendritic cells (an APCs) can also express it. 
In peripheral tissues such as the muscle, the DCs present a high phagocytic capacity 
and a low expression level of costimulatory molecules, rendering them poor initiators of 
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the immune response. Therefore, the uptake by DCs of apoptotic cells expressing the 
Ag in the absence of a danger signal induces cell tolerance162,163. Thus, the 
administration of an Ag by intramuscular vaccination avoids the activation of 
autoreactive T cells by deleting them via apoptosis, rendering them unresponsive 
(anergic) and/or inducing Tregs164,165. AST by intramuscular administration of the Ag 
has obtained encouraging results for the treatment of ADs such as multiple sclerosis or 
T1DM153,166,167.  
 
Liver has a great capacity to induce tolerance168,169. The liver is constantly exposed to 
external Ags that come from the food, inducing tolerance to these Ags. The liver 
presents a particular morphology with sinusoidal and fenestrated vessels that reduce 
the blood flux, allowing the blood to enter into the subendothelial space to facilitate the 
interaction of the carrying molecules from the intestine with the hepatocytes170. Thanks 
to the hepatic microcirculation and considering the number of times that the same T 
cell passes through the liver (around several hundred times per day), the interaction 
between T cells and liver cells is highly probable increasing the possibilities to 
encounter the Ag expressed by these liver cells. Once the T cell arrives, it is exposed 
to tolerogenic mediators such as interleukin-10 (IL-10) or TGFβ171. The interaction of T 
cells with liver cells (DC, Kupffer cells, sinusoidal endothelial cells and hepatocytes) in 
these non-inflammatory conditions induces the anergy state, their deletion or their 
differentiation to iTregs172,173. It has been shown that either by intravenous and 
intraportal administration of the Ag, AST is efficiently induced174–176.  
 
3.1.3. Gene therapy 
 
Gene therapy is the use of a vector to deliver a gene to a target cell with a therapeutic 
aim. Due to the different nature of the vectors currently used in gene therapy, the 
expression of the Ag encoded into the delivered transgene can be modulated. Thus, 
the Ag expression can persist for a long period of time or can be for a short term, it can 
be expressed with low or high intensity and depending on the administration route and 
vector tropism, different cell types can be targeted. Therefore, gene therapy becomes a 
suitable way to induce AST.   
 
3.1.3.1. Advantages and disadvantages of current vectors 
 
The most used gene delivery vehicles for restoring tolerance approaches are based in 
naked DNA in the form of plasmids, or in viral vectors such as lentiviral vectors (LV) or 
adeno-associated viral vectors (AAV). A key question to choose a particular viral vector 
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to induce AST is the intrinsic immunogenicity of the vector particle. In the same way 
that adenoviral-based vectors are the vector particles of choice to induce 
immunogenicity177,178, to induce AST, a vector that do not induce an immune response 
naturally, is needed, otherwise, even a small inflammation caused by the vector during 
the delivering of the self-Ags can exacerbate the immune response instead of inducing 
AST. 
 
Plasmid DNA, if compared to viral vector particles, is easier and cheaper to 
manufacture under good manufacturing practice (GMP) conditions, is more stable and 
safer. As gene delivery vectors they are less efficient than viral vectors and repeated 
doses of plasmid are needed to obtain a comparable transduction efficacy. The use of 
naked DNA as vehicle to induce AST has been tested in the clinic for T1DM patients 
with relative success152,153,179–181. However, the current development of new polymers, 
which are being used to coat plasmid DNA molecules, can enhance their in vivo 
administration significantly.    
 
On the other hand, viral vectors are more efficient than naked DNA to deliver genes to 
target cells, however, they are more expensive at manufacturing and more labile. Both 
LV and AAV transduce a wide variety of tissues. LV mediate a long-term expression in 
vivo because they are integrative, but precisely for this reason, in vivo administration of 
these vectors is not currently approved in humans. AAV-dervied vectors can also 
provide long term expression when the target cells have a very slow division rate, since 
they remain as episomes182–186. These vectors are able to induce AST in naïve 
hosts137,187–190, however, they are not completely non-immunogenic and repetitive 
administrations can induce an immune response towards the vector particles, hence 
jeopardizing the AST. For example, around 60% of the population carries AAV 
antibodies as a consequence of previous infections with the native virus. This 
circumstance prevents the use of AAV-derived vectors 191. 
Therefore, new viral vector systems that completely lack of immunogenicity are 
needed.  
 
3.1.3.2. SV40 as a delivery system for gene therapy in T1DM 
The use of replication deficient Simian Virus 40 particles (SV40) as a gene delivery 
vehicle can avoid many of the above mention problems without losing efficacy to 
induce AST. SV40 is a non-enveloped polyomavirus with an icosahedral capsid of 45 
nm of diameter and with a double strand DNA molecule of 5.25 kb. The genome is 
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organized in a regulatory region that controls the expression of the early genes and the 
late genes. The early genes code for the non-structural proteins, the large T antigen 
(LTag) and small T antigen (STag) and the late genes code for the structural viral 
proteins (VP1, VP2, VP3)192,193. The viral particles replicate in macaques, the natural 
hosts, where it causes chronic asymptomatic infections194. As it enters cells through the 
caveola, viral particles avoid the proteasome degradation and evade the immune 
system195,196.  
 
The lack of immunogenicity of SV40 makes these vectors attractive for use in AST 
induction. Several reports have indicated that SV40 vector particles neither induce the 
generation of neutralizing antibodies nor a T cell reaction upon in vivo administration, 
considering then that humans are naïve for these viral particles197–199. Moreover, SV40 
particles transduce efficiently a wide range of cells, increasing the possibilities of their 
application in the clinic200–203. 
 
These advantages of SV40 particles for their application in gene therapy have led to 
the generation of SV40 delivery vectors in which the removal of the early genes leaves 
2.7 Kb of space to insert the transgene of interest. Nevertheless during the production 
process in the packaging cell line based in CV-1 cells (Cos1), wild type particles can 
emerge, making impossible to use these vector particles in the clinic204. The reason is a 
homology-dependent recombination process that happen between the chromosomally 
inserted SV40-specific DNA sequences and episomally replicating vector-specific DNA 
sequences. To solve this problem, at Amarna Therapeutics a new Vero-based 
packaging cell line has been developed by incorporating into the cells only the 
necessary DNA sequences to express exclusively the LTag preventing in this way the 
recombination process205,206. This SuperVero cell line produces comparable amounts of 
SV40 viral particles as the Cos1 cell line without contamination with replication-
competent SV40 particles206. 
 
3.1.4. Drug therapy 
 
3.1.4.1. BL001 as a novel T1DM therapy  
 
Despite huge efforts to find an effective treatment for T1DM, there is still the necessity 
to identify compounds that can protect the β cells from the attack of the immune 
system, and at the same time can induce the proliferation of new β cells, to repopulate 
the lost tissue and the lost function. Some small drugs targeting proteins involved in 
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inflammation are in development phase, and although they are showing a good 
efficacy, comparable to glucocorticoids, they still cannot achieve long-term 
remission207,208.   
 
A potential target to treat T1DM is the liver receptor homolog 1 (LRH1). LRH1, also 
known as NR5A2, is a member of the NR5A family of nuclear receptors, which plays a 
pivotal role during early embryonic development. This gene is expressed in tissues 
derived from the endoderm including intestine, liver, immune cells and ovary as well as 
exocrine and endocrine pancreas209–211. In the exocrine pancreas, LRH1 regulates the 
expression of genes involved in digestive functions212, while in the endocrine pancreas 
confers protection against stress-induced apoptosis and stimulates the production of 
enzymes involved in the glucocorticoids biosynthesis213. In the immune system, LRH1 
is expressed in different cell types such as macrophages210, primary and secondary 
lymphatic tissues, as well as in CD4+ and CD8+ T cells211. Several lines of evidence 
also support a role for LRH1 in the control of the inflammatory response by inducing an 
anti-inflammatory phenotype in macrophages210, controlling the homeostasis of 
activated CD4+ and CD8+ T cells211, regulating intestinal immunity in response to 
immunological stress214 and modulating the hepatic acute-phase response215. Natural 
phospholipids have been described as activators of LRH1 and present therapeutic 
properties improving glucose homeostasis and decreasing hepatic steatosis216–218. 
According to that, an LRH1 agonist that potentiates the activity of this factor can be 
used as a therapeutic approach to treat T1DM. The initial β cell injury promotes the 
differentiation to proinflammatory macrophage phenotype (M1 subtype) which can 
induce β cell death through the secretion of the pro-inflammatory cytokines IL-1β and 
TNFα. These cells activate T lymphocytes which can produce other inflammatory 
cytokines such as IFNγ. As explained previously, the synergy of the action between 
these three cytokines can promote β cell death219. However, the presence of the anti-
inflammatory macrophage subtype (M2 phenotype), promoted by a LRH1 agonist, can 
block the activation of M1 as well as the T lymphocytes, and the progress of the 
immune attack. This agonist would promote an islet anti-inflammatory environment that 
can prevent the progressive loss of pancreatic β cells, improving the glucose 
homeostasis. In vitro studies demonstrated the protective role of LRH1 against 
cytokines and streptozotocin-induced apoptosis by the overexpression of this 
transcription factor213 as well as by BL001220, a novel LRH1 agonist (patented by Dr. B. 
Gauthier WO 2011-144725-A2 and WO 2016-156531-A1). The experiments performed 
in our group have revealed that daily injections during 24 weeks did not produce 
macroscopic organ alterations in BL001-treated mice, with normal cholesterol and 
30 
 
triglycerides plasma levels up to 8 weeks of treatment. More importantly, our group 
showed that the treatment with BL001 significantly decreases the incidence of 
hyperglycemia. This action is mediated by the regeneration of β cells and, at the same 
time, the promotion of immune tolerance, skewing the pro-inflammatory M1 
macrophages towards the M2 subtype, which is defined by the expression of distinct 
surface markers and the secretion of cytokines such as IL-10 or TGFβ (Figure 9). In 
agreement with this, isolated intraperitoneal macrophages treated in vitro with BL001 
showed a dose-dependent increase in the transcription and secretion of IL-10 and 
TGFβ220. However, further experiments are needed to decipher whether these effects 
on macrophages of BL001 are mediated by LRH1. Similarly, the increase in the M2 
population of macrophages has been associated with a protective effect in several 
preclinical models of autoimmune diseases221,222. Accordingly, a deficient function in 
M2 subpopulation from NOD mice, which present a reduced tolerogenic function, can 
play a role in the susceptibility of this model221,223. 
 
 
Figure 9. Macrophages differentiation to M1 or M2 profile after the treatment with LPS or 
BL001 respectively. Macrophages can differentiate into the proinflammatory phenotype (M1) 
or to the anti-inflammatory phenotype (M2). The production of cytokines by these subtypes can 
interact with other cells and modulate the immune response. Thus, based on our recent 
publication the presence of BL001 can induce the differentiation to the M2 phenotype 
meanwhile the treatment with lipopolysaccharide (LPS) prompts to the M1 subtype.   
 
Despite the benefits of BL001, the translation into humans can present some limitations 
since BL001 cannot be administrated orally due to its lipophilicity. Hence, novel 
compounds that activate LRH1 and are well tolerated when they are administered 
orally should be developed.  
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II. HYPOTHESIS 
 
 
 
The induction of a tolerogenic environment can preserve the survival and function of 
the pancreatic β cells, preventing the development of T1DM. For this end, two different 
approaches are investigated:  
 
- The development of a vaccine based on SV40 viral vector that can restore the 
AST in T1DM by expressing the self- antigen insulin. 
 
- An in vitro screening platform that can allow the identification of novel LRH1 
agonists with an anti-inflammatory capacity.  
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III. OBJECTIVES 
 
 
 
Objective 1. Induction of antigen specific tolerance in the transgenic RIPB7.1 
mouse model by delivery of the insulin gene using SV40 vectors 
 
1. Determine the biosafety of the SV40-packaging cell line Super Vero 
2. Validate the transduction efficiency of the SV40 vectors manufactured 
with SuperVero cells in vivo  
3. Setting up the conditions to induce antigen specific tolerance in the 
transgenic mice RIPB7.1 
 
Objective 2. LRH1 as a novel target to treat T1DM: Analysis of the effect of LRH1 
agonist BL001 on the innate immune system and screening for a second 
generation of LRH1 agonists 
 
1. Effect of the LRH1 agonist BL001 in primary macrophages 
2. Screening of novel LRH1 agonists  
2.1. Development of a screening platform  
2.2. Screening novel LRH1 agonists and their safety profile  
2.3. Evaluation of the protective capacity of two novel LRH1 agonists 
in vitro 
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IV. MATERIALS AND METHODS 
 
 
 
Mice 
RIPB7.1 mice were housed in ventilated plastic cages under a 12 hours light/dark 
cycle, with food and water ad libitum. Mice experimentations were approved by the 
CABIMER Animal Committee, and performed in accordance with the Spanish law on 
animal use RD 53/2013. Mice genotyping was performed by PCR using a tail sample 
obtained at day 10 after birth. For genomic DNA extraction and transgene amplification 
from mouse tails the REDExtract‐N‐AmpTM Tissue PCR Kit (Sigma‐Aldrich; 
#031M6112) was used. PCR was performed with the specific primers for the B7 
transgene (Table I). Several in vivo parameters were assessed as described below: 
 
a. Immunization.  
For the EAD induction (immunization), 7 to 8 week-old RIP-B7.1 mice (males and 
females) were injected with 50µg of human ppINS expression pCI plasmid (Plasmid 
Factory GmbH, Germany) diluted in PBS into each of the two anterior tibialis 
muscles (50µl per injection). Glucose monitoring was performed weekly on blood 
samples from tail vein using on the Optium Xceed glucometer (Abbott Scientifica). 
Non-fasting blood glucose higher than 300mg/dl for two consecutive measurements 
was considered hyperglycemia. At the end of the experiments mice were 
euthanized and pancreases were extracted for immunohistochemistry assays. 
  
b. DNA vaccination/ SV40 administration 
DNA vaccines or SV40 vector particles were administrated diluted in PBS through 
different approaches: intramuscularly in the anterior tibialis muscles (in a final 
volume of 50µl), intravenously by the tail vein injection (in a final volume of 100µl) 
or hydrodynamically considering the 10% of weight (in grams) of the mice. 
 
c. Alanine aminotransferase determination 
Blood samples were collected from the facial vein of mice. Consecutively, serum 
alanine aminotransferase (ALT) was measured using the Reflotron GPT (ALT) Test 
(Roche, #10745138) according to the manufacturer’s instructions.  
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d. In vivo imaging to assess biodistribution of viral/DNA particles harbouring 
luciferase 
Pierce D-luciferin (Roche, #88293) was resuspended in PBS at a final 
concentration of 15mg/ml. Then, D-Luciferin was administrated into the tail vein, 
receiving each mouse 150 mg D-Luciferin/kg body weight. 5 minutes post-injection, 
luciferase signal was measured using the Xenogen in vivo imaging system (IVIS).  
 
e. Measurement of anti-SV40 antibodies 
Serum samples obtained from facial vein puncture from SV40 injected mice were 
heat-inactivated at 56°C for 30 min. As a control, serum of non-SV40 injected mice 
was included. All the samples were serially diluted with PBS (1/10, 1/50 to 1/100) 
and mixed with equal volumes of SVGFP viral particles. The mixtures (vector-
serum dilutions) were incubated at 37°C for 30 min. One day after seeding of Cos1 
cells in 96 multiwell plate, they were inoculated with 50 µl of vector–serum mixture 
and incubated for 4 hours at 37°C in a humidified 5% incubator. Fresh DMEM 
media was then added to each well and seven days after transduction, GFP was 
measured using Varioskan Flash spectrophotometer (Thermo Scientific). Every 
sample was tested in triplicate. A negative control without transduction was 
included in each experiment.  
 
Islets isolation 
Mice were sacrificed by cervical dislocation and pancreatic islets were isolated by 
collagenase perfusion (Sigma-Aldrich, #C9263) digestion, handpicked and maintained 
in RPMI 1640 at 11.1mM glucose (Sigma-Aldrich; #R0883) supplemented with 10% 
heat inactivated FBS (Sigma-Aldrich, #F7524), 2mM L-glutamine (Sigma-Aldrich, 
#G7513), 10mM HEPES (Gibco, #15630-056), 100 units/mL penicillin, and 100 µg/mL 
streptomycin (Sigma-Aldrich, #P4333), 1mM sodium pyruvate (Sigma-Aldrich, #S8636) 
and 50µM β-mercaptoethanol (Gibco, #31350-10).  
 
Cytokines-induced apoptosis  
Mouse islets were cultured in RPMI medium containing 10% charcoal-stripped FCS for 
48 h. The latter is nearly free of endogenous steroids to avoid the deviation of the 
results. Islets were then cultured for 48 hours in the presence of different 
concentrations of the compounds (BL002 and BL003) at 0.05% of DMSO, alone or in 
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combination with a cocktail of cytokines (2 ng/ml IL-1β, 28 ng/ml TNFα and 833 ng/ml 
IFNγ) added 24 hours before ending the experiment.  
 
Primary macrophages 
a. Macrophage isolation 
Intraperitoneal macrophages were isolated after CO2 euthanasia to avoid excessive 
bleeding into the peritoneal cavity. Then, the skin was removed and 10ml of cold 
Dulbecco’s phosphate-buffered saline F12/10 without calcium and magnesium 
(Sigma-Aldrich, #D8437) was injected into the intraperitoneal cavity. Subsequently, 
the peritoneum is gently messaged to remove any attached cells. The volume is 
harvested and collected in ice cold tubes which are centrifuged at 4°C for 10 
minutes at 1500rpm. To eliminate the erythrocytes present in the sample, cell 
pellets are incubated with blood lysis buffer for 5 minutes at room temperature 
(Sigma-Aldrich, #R7757) and washed twice with supplemented media containing 
10% (vol/vol) heat‐inactivated fetal bovine serum (FBS), 100U/ml penicillin, 
100μg/ml streptomycin, 2mM L-glutamine, 10mM HEPES, 1mM sodium pyruvate 
and 50μM β‐mercaptoethanol. Intraperitoneal macrophages were seeded in non-
adherent plates for one week to obtain a purified macrophage population.   
 
b. LRH1 silencing macrophages 
Intraperitoneal macrophages were transfected with ON-TARGETplus SMARTpool 
siRNA targeted to mouse LRH1 (Dharmacon, #L003430) or a control luciferase 
siRNA (Sigma, #HA10574568) at 50nM using the transfection reagent Viromer Blue 
(Lipocalyx, #VB-01LB-00) according to the manufacturer´s instruction. 24 hours 
after transfection, primary cultures of intraperitoneal macrophages were treated 
with BL001 (10µM) or LPS (1µg/ml), which induces a pro-inflammatory profile in 
control macrophages. Then, 24 hours after treatment (48 hours after transfection), 
cells were collected for RNA extraction.  
For immunocytochemistry analysis, macrophages were seeded in 12mm diameter 
glass coverslips (Menzel‐Glaser, #J1800AMNZ) in 24 multiwell plates. After 
obtaining the pure macrophage culture, LRH1 was silenced as previously indicated 
and immunocytochemistry was performed 48 hours after silencing.   
 
Cell culture  
All cell lines were incubated in a humified (95%) atmosphere (5% CO2) at 37°C in 
media supplemented with 10% (vol/vol) heat‐inactivated fetal bovine serum (FBS), 
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100U/ml penicillin, 100μg/ml streptomycin and 2mM L-glutamine. However, some 
exceptions have to be mentioned: SuperVero media was only supplemented by L-
glutamine and HepG2 media contains 20% of FBS.  
 
Monkey kidney fibroblast Vero and SuperVero cell lines (obtained from Amarna 
Therapeutics) were cultured in serum-free OptiPRO (Gibco, #12309019) medium. Cell 
monolayers at 90‐95% confluency were digested by exposure to trypsin (Gibco, 
#15400054) to harvest the cells for sample preparation or culture passage. Passages 
were performed twice per week and media was changed every three days. 
 
Murine macrophages Raw 264.7, monkey kidney fibroblast Cos1 and human 
embryonic kidney 293T cell lines were cultured in supplemented (as previously 
indicated) Dulbecco's modified eagle medium (DMEM) (25mM glucose). To harvest 
cells for sample preparation or culture passage, cell monolayers at 90‐95% confluency 
were trypsinized. Media was changed every three days and passages were performed 
twices per week. 
 
Human hepatoma HepG2 (kindly provided by Dr. Francisco Martin (GENYO-Granada)) 
and HeLa cell lines were cultured in supplemented Eagle's Minimum Essential Medium 
(EMEM) media. To harvest cells for sample preparation or culture passage, cell 
monolayers at 80‐90% confluence were trypsinized. Passages were performed twice 
per week and media was changed every three days. 
 
The rat insulinoma cell line Ins-1E (kindly provided by Claes Wollheim (University of 
Geneva, Switzerland)) was cultured in RPMI‐1640 medium at 11.1mM glucose 
supplemented with 10mM HEPES, 1mM sodium pyruvate and 50μM β‐
mercaptoethanol. When confluence was approximately 80‐90%, cells grown in TPP 
tissue culture flasks (TPP, #90076) were trypsinized. Passages were performed once 
weekly when cells reach 80-90% confluence and media was changed every three 
days.  
 
Jurkat cell line was cultured in RPMI‐1640 medium at 11.1mM glucose. A density of 
1x105 viable cells/mL was maintained during the culture. Every three days, density was 
corroborated to avoid exceed 3x106 cells/ml and media was changed.  
 
Primary macrophages were isolated and cultured in non-adherent plates (Greiner, 
#658170) in supplemented Dulbecco’s phosphate-buffered saline F12/10 without 
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calcium and magnesium media supplemented with 10% (vol/vol) heat‐inactivated fetal 
bovine serum (FBS), 100U/ml penicillin, 100μg/ml streptomycin, 2mM L-glutamine, 
10mM HEPES, 1mM sodium pyruvate and 50μM β‐mercaptoethanol. Media was 
replaced every three days.  
 
Creation of the screening platform  
For the creation of a stable cell line expressing GFP under the transcriptional control of 
the LRH-1 target SHP gene promoter, SHP-HepG2 (Figure 10), HepG2 cells were 
seeded in 24 multiwell plates and transduced with LV-SHP-GFP vectors with a 
multiplicity of infection (MOI) of 2. One month after transduction (10 passages post-
transduction), GFP positive cells were analyzed by flow cytometry using FACSCalibur 
(BD Biosciences) showing a 50% of positive population. Then, LV-SHP-GFP vector 
copy number was determined by Q-PCR using the sequence Woodchuck hepatitis 
virus post-transcriptional regulatory element (WPRE) present in the vector, considering 
the DNA amount corresponding to 100.000 cells (600ng of genomic DNA from the 
cultured cells). The analysis showed that the culture has an average of 0.4 copies per 
cell, confirming the FACS data where, after the analysis of GFP population, around 
50% of cells were positive for this fluorescence protein. GFP was measured every 
week during one month, keeping the percentage of GFP positive cells stable.  
Then, these SHP-HepG2 cells were transduced with at MOI 1 using LV-EF1α-DsRed 
vectors. This promoter reporter construct was used as control non LRH-1 target. One 
week post-transduction, initial analysis using flow cytometry showed a 20% of GFP-
DsRed-double positive cells. Two sorting processes using the FACSARIA I (BD) were 
necessaries to obtain a purity of 60% of GFP-DsRed-double positive cells. The EF1α-
DsRed lentiviral copy number was determined by Q-PCR using specific primers for this 
transgene, showing 0.5 copies per cell. SHP/EF1α-HepG2 cells were expanded in 
culture medium, stored in liquid nitrogen and used for screening experiments. After 20 
passages in culture, the expression of both transgenes remained constant revealing 
that these LV do not affect cell viability.  
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Figure 10. Production of the screening platform SHP/EFα HepG2 cell line. Schematic 
representation of the transduction steps using two different lentiviral vectors and subsequent 
selection of double positive cells by sorting. After transduction with LV-SHP-GFP, 50% of cells 
were GFP positive. Consecutively, the transduction with LV-EF1α-DsRed resulted in a 20% of 
double positive cells which were purified after two sorting processes to obtain a 60% of 
SHP/EF1α HepG2 cells.  
 
DNA plasmid production 
a. Cloning strategy 
Human preproinsulin sequence from phppINS was used to create pSVPPI plasmid, 
which was cloned by Amarna Therapeutics BV.  
 
In the case of proinsulin vectors, proinsulin was obtained from a purchased plasmid 
(GeneArt, ThermoFisher) containing proinsulin with the microRNA target sequence 
(miRT) 142·3p. The addition of this sequence prevents the expression of the 
transgene in hematopoietic cells such as APCs, which can improve the outcome of 
AST. First, proinsulin transgene together with the miRT-142·3p was cloned into 
pSV40 plasmid using ClaI (New England Biolabs, #R0197) and XbaI (New England 
Biolabs, #R0145), generating pSVProI-142·3p. Then, in order to produce the 
pSVGFP-142·3p or pSVLuc-142·3p plasmids, ProI transgene was removed using 
SpeI (New England Biolabs, #R0133) and XhoI (New England Biolabs, #R0146), 
being GFP or Luc inserted into these sites respectively. To delete the miRT 
sequence and obtain pSVProI, the enzyme AscI (New England Biolabs, #R0558) 
was used and generating this plasmid.  
Afterwards, plasmids have been sequenced to confirm the correct insertion of the 
transgenes and the absence of mutations.  
 
b. DNA plasmid amplification  
Transformation of Stble3 bacteria  
39 
 
50ng of DNA was added to 50μl of Stble3 (Invitrogen, # C737303) competent 
bacteria for transformation. After incubation for 30 minutes on ice, a heat‐shock at 
42°C was performed for 45 seconds. Then, 450μl of Luria Broth (LB, Sigma‐Aldrich; 
#L3022) medium was added and the suspension was incubated for 30 min at 37°C 
shaking. 100µl of bacterial suspension was plated on LB plates containing 1mg/ml 
ampicillin). Plates were incubated at 37 °C overnight. 
 
Purification of DNA plasmids 
For preparation of plasmid containing bacteria, single colonies were hand-picked 
and transferred to 5ml LB medium containing 1mg/ml ampicillin. Tubes were 
incubated shacking at 37°C overnight. Plasmid purification was performed 
according to the manufacturer´s instructions (Qiaprep Spin MiniPrep kit (Qiagen; 
#27106). 
 
DNA plasmid amplification 
Once the plasmids have been corroborated by restriction enzymes digestion, the 
positive clones were used to inoculated 500ml of LB medium containing 1mg/ml 
ampicillin and incubated at 37°C overnight shaking. Then, purification of plasmid 
DNA was performed according to the manufacturer´s instructions (Qiagen Plasmid 
Maxi Kit (Qiagen, #12963). DNA concentration was measured using NanoDrop 
(NanoDrop 2000c; Thermo Scientific). 
 
Transfection of culture cells 
To assess expression levels of pSVProI and pSVPPI, 293T were seeded in 12 
multiwell plates and transfected using lipoD293 (Signagen, #SL100668) with these 
plasmids, including phppINS and pSVGFP according to the manufacturer´s 
instructions. Four hours post-transfection, media was replaced and cells incubated for 
48 hours. Twelve hours prior to the end of the experiment, the proteasome inhibitor 
MG132 (Sigma-Aldrich, #M8699) was added to the cells at 10µM. Then, protein 
isolation was performed.  
 
In the case of immunocytochemistry, 293T cells were seeded in 12mm diameter glass 
coverslips in 24 multiwell plates. Then, cells were transfected using lipoD293 with 
pSVPPI, pSVProI, phppINS and pSVLuc plasmids according to the manufacturer´s 
instructions. Four hours post-transfection, media was replaced and cells incubated for 
48 hours for immunocytochemistry.  
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In order to evaluate whether the presence of miRT 142·3p can prevent the expression 
of the transgene in APCs and induce AST, the expression levels were assessed in 
different cell lines both hematopoietic and non-hematopoietic. HepG2, Raw 264.7 and 
Jurkat cells were seeded in 24 multiwell plate and 24 hours after, transfected with 
pSVGFP or pSVGFP-142·3p using Lipofectamine 2000 (Invitrogen, #11668-030) 
according to the manufacturer´s instructions. Intensity and percentage of GFP positive 
cells were measured through flow cytometry FACSCalibur (BD Biosciences) 48 hours 
post-transfection. 
 
To validate if increasing amounts of LRH1 can enhance SHP promoter activity in the 
SHP/EFα HepG2 cell line, and, consequently increase the amount of GFP, they were 
seeded in a 24 multiwell plates and transfected with increasing amounts of pCMV-
LRH1. Increasing amounts of plasmid was used to transfect these cells with 
Lipofectamine 2000 according to the manufacturer´s instructions. Four hours post-
transfection, media was replaced. Intensity and percentage of GFP positive cells were 
measured through flow cytometry using FACSCalibur at 72 hours post-transfection. 
 
Viral vector production 
a. SV40 vector production  
For the production of SV40 vectors, SuperVero cells were used. This procedure 
was carried out by Amarna Therapeutics B.V. In brief, SV40 plasmids were 
digested with NotI (New England, #R3189S) to remove the bacterial backbone. 
Then, these plasmids were isolated from agarose gels and re-circularized using T4 
ligase (New England Biolabs, #M0202). SuperVero cells are transfected with these 
plasmids and viral vectors are harvested 72 hours post-transfection. This vector-
containing media is used to subsequent transduction rounds. At least two cycles 
are performed using MOI 400. After harvest, vectors are cleared and concentrated 
by ultracentrifugation, and stored at 4°C until their use.  
 
b. SV40 quantification 
DNA was isolated from liver tissue using phenol:chlorophorm (Sigma-Aldrich, 
#77617). DNA concentration was measured using a spectrophotometer 
(NanoDrop1000; Thermo Scientific). 600ng corresponding to 105 cells was used to 
quantify the number of SV40 copies per cell. For the determination of number of 
vector particles, quantitative Taqman PCR was performed. The structural gene VP2 
was used to determine the copy number (using the proof with the sequence:  
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5´- AATTGCTGCTATAGGCCTC-3´)). Samples were analyzed in duplicates, using 
Taqman mix (Applied Biosystem, #4304437).  
 
c. Lentiviral vector production 
The DNA sequence corresponding to the human SHP promoter was ordered and 
assembled from PCR products. The fragment was cloned into the pMA (ampR) 
plasmid (Life technologies) using KpnI (New England Biolabs, #R0142S) and SacI 
(New England Biolabs, #R0156S) cloning sites, obtaining the pMA-SHP plasmid.  
 
To construct the vector LV-SHP-GFP, the plasmid pMA-SHP was digested using 
the restriction enzymes EcoRI (New England Biolabs, #R0101S) and BamHI (New 
England Biolabs, #R0136S). A band of an approximated size of 594 base pairs was 
recovered from the agarose gel and the DNA was isolated. The fragment was 
cloned into the lentiviral plasmid backbone CMV-GFP-WPRE that was previously 
digested with the restriction enzymes EcoRI and BamHI to release the CMV 
promoter. The result was the vector LV-SHP-GFP in the plasmid form. In the case 
of LV-EF1α-DsRed vector, plasmid construct was kindly provided by Dr. Francisco 
Martin (GENYO, Granada).  
 
For the lentiviral production, these plasmids were cotransfected with the 
pCMVDR8.91 and pMDG. To do so, 293T cells were seeded in a 10cm Petri dish 
and transiently transfected 24 hours after using LipoD293 according to the 
manufacturer´s instructions. Plasmids used for transfection were: 1) 7.5µg of 
pSHP-GFP or pEF1α-DsRed, 2) 5µg of pCMVDR8.91 and 3) 2.5µg of pMDG to 
each plate. Four hours after transfection, media was replaced. Lentiviruses were 
harvested 48 and 72 hours post-transfection. Media was centrifuged for 5 minutes 
at 4°C at 1500rpm and filtered using 0.45 µm PVDF filters Millex- HV (Merk 
Millipore, #SLHV033RS) and concentrated by ultracentrifugation in an Optima L-
100K ultracentrifuge at 22000rpm for 90 minutes at 4ºC in a swinging bucket rotor 
SW-28 (Beckman-Coulter). Pellets were resuspended in serum-free DMEM and 
viral particles were distributed in aliquots and stored at −80 °C. 
 
d. Titration of lentiviral vectors  
To determine the quantity of the lentiviral vector production, 5x104 293T cells were 
seeded in 24 multiwell plates. Increasing volume of the lentiviral suspension was 
added to the wells 24 hours post-seeding. Cells were harvested 72 hours post-
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transfection to determine the percentage of GFP or DsRed positive cells by flow 
cytometry. To determine the titer, the number of positive cells was considered as 
well as the volume added to each well. Average of the different conditions was 
calculated.   
 
Q-RT-PCR 
a. RNA isolation 
RNA from 293T cells was isolated using the RNeasy mini kit (Qiagen, #74106) 
according to the manufacturer’s instructions. An intermediate treatment with Turbo 
DNAse (2U/µg RNA) (Ambion, #AM2238) for 30 minutes at 37ºC was included to 
remove traces of DNA contamination.  
 
In the case of primary intraperitoneal macrophages, RNA was extracted using the 
commercial kit RNeasy Micro kit (Qiagen, #74004) according to the manufacturer´s 
instructions. RNA concentration was measured using a spectrophotometer 
(NanoDrop1000; Thermo Scientific). An Agilent 2100 Bioanalyser was used to 
determine the RNA integrity number (RIN). RNA samples with 260/280 ratios in the 
range of 2.0 to 2.2 and RIN 7‐10 were selected for further analysis. 
 
b. Complementary DNA synthesis: 
To synthesize the cDNA, 1μg of total RNA was used in the case of the cell lines, 
and 600ng from the primary macrophages. These RNA samples were converted 
into cDNA using random hexamers (10x concentrated) (Roche, #11277081001) 
and Superscript II Reverse transcriptase with a concentration of 50U/µl (Invitrogen; 
#18064‐014) following the manufacturer’s instructions.  
 
c. Q-RT-PCR 
Quantitative PCR was performed using an ABI 7000 Sequence Detection System 
(Applera Europe) and using the FastStart Universal SYBR Green Master (Roche, 
#04913850001). The reactions were performed in duplicate for each sample, and 
normalized to the housekeeping gene, cyclophylin in the case of samples from 
human cell lines and β‐actin for the murine primary cells. Primers are specified in 
table I.  
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 Forward Reverse 
B7 CAAACAACAGCCTTACCTTCGG GCCTCCAAAACCTACACATCCT 
hSHP1 ATCCTCTTCAACCCCGATGT TCCAGGACTTCACACAGCAC 
hLRH1 CCGACAAGTGGTACATGGAA TCCGGCTTGTGATGCTATTA 
hCYCLO CCATTTGTGTTGGGTCCAGC TACGGGTCCTGGCATCTTGT 
hPROI AGGCTTCTTCTACACACCCAAG CACAATGCCACGCTTCTG 
mβ-actin GCTCACCCTTACCTGGAACA GGACCAGATCCAAAAGGACA 
SV40 ACTTGCATCTGTTGCTACTGTTGA GCCCCAGATATCACAGCATAGG 
mIL-10 CAGAGCCACATGCTCCTAGA GGCAACCCAAGTAACCCTTA 
mTGFB GCCCTGGATACCAACTATTGC AAGTTGGCATGGTAGCCCTT 
mLRH1 ATGCCCTCTGACCTGACCATT GGTTCAGAGGTAGGCCTTTGG 
WPRE CGCTGCTTTAATGCCTTTGT GTTGCGTCAGCAAACACAGT 
DsRed CGACATCCCCCGACTACAAAGA TTCACGCCGATGAACTTCAC 
 
Table I. Primers used to perform the PCRs.  
 
Protein isolation and Western Blot 
For protein isolation, cells at 90% confluence were washed with PBS and frozen in 
liquid N2. Then, cells were collected in RIPA buffer (Sigma-Aldrich, #R0278) containing 
1X Protease Inhibitor Cocktail Tablets SigmaFast (Sigma‐Aldrich, #S8820), incubated 
for 1 hour at 4°C with rotation and centrifuged at maximum velocity for 5 min at 4°C. 
Protein content of the supernatant was determined using the Quick Start Bradford 1X 
Protein Assay Kit (Bio‐Rad, #500‐0205) at 562 nm.  
 
Then, 20µg of total protein was mixed with dithiothreitol (DTT) (Sigma‐Aldrich, #43816) 
for a final concentration of 20mM and 1x loading buffer (250mM TrisHCl pH 6.8, 0.5% 
bromophenol blue/5% SDS/50% glycerol). Samples were heated at 95°C for 5 min and 
separated by 10% SDS‐PAGE for 1 hour at 110mV. Afterwards, proteins were 
transferred by semi-dry transference to a PVDF membrane (Gibco, #RPN303F) using 
TransferBlot Turbo (BioRad). After that, the membrane was blocked with 5% Bovine 
serum albumin (BSA) (Sigma‐Aldrich, #A3294) in TBST (NaCl 0.19 M/Tris‐HCl pH 7.5 
0.05M/0.1% Tween 20 (Sigma‐Aldrich, #P2287)) for 1 hour at room temperature and 
subsequently incubated overnight at 4ºC with corresponding primary antibodies diluted 
in 3% BSA in TBST. Primary antibodies used are: 1:200 for rabbit polyclonal anti-
insulin (Santa Cruz Biotechnology, #SC-9468), 1:1000 for goat polyclonal anti-GFP 
(Abcam, #ab6673), 1:5000 for mouse monoclonal tubulin (Sigma-Aldrich, #T9026), 
1:200 for mouse anti-SV40 Tag (Abcam, #ab16879), 1:5000 for rabbit anti-VP1 
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(Abcam, #ab53977) and 1:5000 for mouse anti-GAPDH (Millipore, #ab2302). After 
primary antibody incubation, the membranes were washed with TBST and incubated 
with the corresponding HRP secondary antibody diluted in 1% BSA in TBST for 1 hour 
at room temperature. Secondary antibodies used are: anti-goat IgG peroxidase 
conjugated at 1:5000 (Sigma-Aldrich, #B8520), anti-rabbit IgG peroxidase conjugated 
at 1:5000 (Sigma-Aldrich, #A0545) and anti-mouse IgG peroxidase conjugated at 
1:5000 (Sigma-Aldrich, #A9044). After washing, immunodetection was performed using 
the ECL Western Blotting SuperNova detection reagent (Cyanage, #XL53) by 
chemiluminescence (Chemidoc MP Imaging System).  
 
Pancreas immunohistochemistry 
Mice pancreas were fixed in 4% paraformaldehyde overnight at 4°C. After washing in 
PBS, the pancreases were dehydrated, embedded in paraffin and sectioned into 5μm 
slices at the Histology platform at CABIMER. Sections were mounted on SuperFrost 
Plus slides (Menzel‐Glaser). Every 10 sections, one slide was stained with 
hematoxylin‐eosin. 
 
Sections heated at 60°C were deparaffinized in xylene and rehydrated in decreasing 
concentrations of ethanol, followed by several washes in water (Xylene 5min/2x; 
Ethanol 100% 1min/2x; Ethanol 90% 1 min; Ethanol 80% 1 min; Ethanol 70% 1 min; 
water). Then, sections were subjected to antigen retrieval using 10mM sodium citrate 
buffer (pH 6.0) in the autoclave (AES-8 Trade Raypa) and cold down for 20 minutes at 
room temperature. After washing twice with PBS and once with PBS/ 0.5% Triton X‐
100 (Sigma‐Aldrich, #T8787), blocking was performed with PBS/0.1% Triton X‐100 
containing 3% BSA for 1 hour at room temperature. Primary antibodies were diluted in 
PBS/ 0.1% Triton X‐100 containing 3% BSA and incubated for 1 hour at room 
temperature in a humid chamber. Concentrations of antibodies used were: 1:200 for 
rabbit polyclonal anti-insulin (Santa Cruz Biotechnology, #SC-9468) and 1:200 for 
mouse monoclonal anti-glucagon (Sigma-Aldrich, #G2654). After washing with PBS, 
sections were incubated with the corresponding secondary antibodies at 1:800 diluted 
in PBS/0.1% Triton‐100 for 1 hour at room temperature in dark. Secondary antibodies 
used were: Alexa Fluor 488 goat anti-rabbit IgG (Invitrogen, #A11008) and Alexa Fluor 
568 goat anti-mouse IgG (Invitrogen, #11004).Nuclear counterstaining was performed 
by DAPI at 1µg/ml (Sigma‐Aldrich, #D9542) after 5 minutes of incubation, and sections 
were mounted using DAKO fluorescent mounting medium (Dako Diagnostics; #S3023). 
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Immunocytochemistry 
Samples were fixed in 4% paraformaldehyde (Sigma‐Aldrich, #P6148) for 10 min at 
room temperature. Then, permeabilization was performed using ice‐cold methanol 
100% for 2 minutes at ‐20ºC. After three washes with PBS/0.1% Tween 20, cells were 
exposed to rabbit polyclonal anti-insulin (Santa Cruz Biotechnology, #SC-9468) at 
1:200 diluted, rabbit polyclonal anti-LRH1 (Abcam, #ab189876) or 1:200 for mouse 
anti-SV40 Tag (Abcam, #ab16879) in 3% BSA/0.1% Tween 20 in PBS for overnight at 
4°C. Controls without primary antibodies were used for each experiment. Afterwards, to 
remove the excess of antibody, coverslips were washed three times in PBS/0.1% 
Tween 20 and incubated with Alexa Fluor 488 goat anti-rabbit IgG (Invitrogen, 
#A11008) or with Alexa Fluor 488 goat anti-mouse IgG (Invitrogen, #A-11001) both at 
1:500 in PBS/0.1% Tween 20 for 1 hour at room temperature in dark. Samples were 
then washed three times with PBS/0.1% Tween 20 for 5 min each. Nuclei staining was 
performed using 1μg/ml DAPI for 5 min at room temperature. Coverslips were mounted 
using DAKO fluorescent mounting medium and left to dry overnight at 
4°C.Fluorescence microscopy images were acquired using a Leica DM6000B 
microscope (Leica Microsystem). 
 
MTT assay 
Ins-1E cells were plated in triplicates in 96 multiwell plates. On the next day, cells were 
cultured with fresh RPMI media containing various concentrations of compounds at 
0.05% DMSO. Cellular viability were assessed by MTT (3-(4,5-dimethylthiazolyl-2)-2,5-
diphenyltetrazolium bromide) assay (Roche, #11465007001) following the 
manufacturer´s instructions after 24 or 48 hours post-treatment. The percentage of cell 
viability was calculated relative to untreated cells.  
 
Proliferation assay 
HepG2 cells were plated in 24 multiwell plates. One day after seeding, cells were 
treated at different concentrations with BL002 or BL003 at 0.05% of DMSO. Then, 48 
hours after treatment, proliferation of cells was assessed using BrdU proliferation 
ELISA assay (Roche, #11647229001) according to the manufacturer´s instructions. 
The proliferation index was calculated relative to untreated cells. 
 
Cell death assay 
HepG2 cells were seeded in 24 multiwell plates. On the next day, cells were treated at 
different concentrations of BL002 or BL003 at 0.05% DMSO. Cell death ELISA (Roche, 
#11544675) assay was performed after 48 hours of treatment according to the 
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manufacturer´s instructions. The cell death index was calculated relative to untreated 
cells. 
 
For the cytokines-induced apoptosis in primary mouse islets, after the treatment with 
BL002 or BL003 as well as the cytokines, cell death ELISA assay was performed 
according to the manufacturer´s instructions. The cell death index was calculated 
relative to non-cytokines-treated islets. 
 
RTCA assay 
HepG2 cells were plated in a 16 e-multiwell plate and incubated at 37°C using the X-
cellygence (ACEA Bioscience). Twenty four hours after seeding, different range of 
concentrations of BL002 or BL003 were used, measuring the cell index constantly until 
the end of the experiment. Cell index relative to time point 0 hours, a quantitative 
measure of the status of the cells in an electrode-containing well, was calculated.  
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V. RESULTS 
 
 
This section has been suppressed in this version according to the confidential 
agreement. 
   
48 
 
 
 
VI. DISCUSSION 
 
 
T1DM is an AD with an alarming increasing prevalence. During the development of this 
disease, the autoimmune destruction of the insulin producing  cells leads to a severe 
condition in which insulin deprivation causes a hyperglycemia with dangerous 
consequences. Currently the only therapy is based on the administration of insulin or 
insulin analogs upon a continuous surveillance of blood glucose levels. However, this is 
a palliative therapy that does neither cure the disease nor prevent secondary 
complications, leading to a severe health condition to the patients. Thus, the 
development of novel effective therapies is imperative. Because the intrinsic cause of 
T1DM as other ADs is the breakdown of the tolerance, the ideal therapeutic treatment 
must follow the restoration of the tolerogenic environment. In this thesis, two different 
approaches have been presented: a SV40-based gene therapy and a pharmacological 
therapy targeting LRH1. 
 
1. Induction of antigen specific tolerance in the transgenic RIPB7.1 mouse model 
by delivery of the insulin gene using SV40-derived vectors 
 
The delivery of self-Ags under non-inflammatory conditions is effective to restore the 
broken tolerance (if administered after the disease has started) or to prevent it (if 
administered before the disease has started) 152,153. This is because this procedure 
resembles the clonal deletion process mediated by thymocytes in the “central 
tolerance” and the Ag presentation by APCs happening in the “peripheral tolerance” 237. 
The key question is to find gene delivery vectors that do not induce an immune 
response by their selves, and therefore, do not induce an inflammatory process instead 
of a tolerogenic one. In humans, on the contrary as it can be done in preclinical 
models, AD can only be treated once they have started, because currently there are 
not available markers that, with 100% accuracy, can predict an imminent development 
of an AD in a person. This circumstance makes that auto-reactive T cell clones have 
been already activated. They are more sensitive to the presence of the Ag than naïve T 
cell clones, and therefore, easier to re-activate and more difficult to inactivate. 
Therefore, a completely inert or non-immunogenic vector is needed, to ensure the 
success of the AST induction in humans.  
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The lack of immunogenicity of SV40 shown by others and by us 238–240, pinpoints at this 
vector as the optimal candidate to be used to treat ADs by restoring the AST 241. We 
have overcome the main problem that avoided the use of SV40-derived vector particles 
in the clinic204,242–244, by the generation of SuperVero. SuperVero cells represent the 
only SV40 packaging cell line able to produce safe replication deficient SV40 vector 
particles, without the risk of contamination with recombination competent SV40 vectors 
206. SuperVero derives intentionally from Vero cells, which are permissive to SV40, and 
also they are accepted by the World Health Organization for human vaccines 
production 245. The expression only of the LTag in SuperVero is sufficient for the 
replication and packaging of SV40 vector particles being enough to activate the 
transcription from the viral late promoter, resulting in the accumulation of capsid 
proteins as well as the SV40 vector production. The absence of STag improves the 
safety due to the reduction of SV40 viral genome necessary to produce the particles 
without interfering the high production of SV40 particles. The generation of SuperVero 
may represent a significant step forward in the treatment of ADs, as soon as the SV40 
vector particles are proven to be effective for such end. 
According to previous publications197–199,225, our results also show that the in vivo 
administration of SV40 vectors does not interfere with the regular function of the liver, 
and more importantly, does no induce the activation of the immune system. The lack of 
immunogenicity resides in two main mechanisms. First, the pathway that SV40 
particles follow during the entrance 196 that avoids the proteasome degradation and the 
MHC presentation, and second, the lack of the presence for long time the viral capsids 
in the target cells, as it has been described to happen for other vectors 246. The 
absence of finding SV40 neutralizing antibodies in treated mice after the vector 
administration is in favor. We would agree that before to reach the clinical studies, 
more exhaustive toxicological/immunological experiments should be performed, but 
these are advantages that other gene therapy vectors such as AAV-based vectors do 
not display. Thus, the presence of AAV neutralizing antibodies in most of the half of the 
human population reduces the number of eligible candidates to be treated with AAV 
vectors
191
. Or as it has been done in some cases, a strong regime of 
immunosuppressors has been co-administered to the patients together with the vector 
particles, to prevent the immune response toward the vectors 247,248. SV40 particles will 
avoid these problems, allowing also their re-administration, for those cases that it 
would be needed, adding another advantage over AAV.  
 
The induction of AST does not need a continuous expression of the self-Ags 
122,149,249,250. Probably, the longer the Ag presentation the longer the risk, as an 
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independent inflammatory process happening at the same time could invert the 
beneficial effect of the self-Ag presentation from a tolerogenic restoration into an 
inflammatory relapsing stage. Thus, if the vector used is able to keep the expression of 
the Ag for a certain period of time would be suitable to efficiently induce AST. SV40 
viral particles remain as episomes in infected cells194,200,251 and the SV40-derived 
vector particles do the same. We show here that the duration of the expression of a 
gene (Luciferase) delivered by intravenous administration of SV40 particles is 
temporary. Others also have shown similar results with SV40, although the detection of 
the transgene was more prolonged than in our case, a circumstance that can be due to 
the dose or efficacy at the time of administration 225.   
These results are interesting because the treatment of AD, compared to other diseases 
treated by gene therapy, includes a layer of complexity, which is based in what we can 
call: “opportunity”. The immune attack in ADs use to progress in “waves”, that is 
because usually the patients show relapsing-remitting stages. Therefore, the way, 
when and for how long the Ag is presented is crucial. Preclinical studies have shown 
that in some cases, a long-term expression of the Ag is necessary to induce 
AST122,137,140,149,252 meanwhile in others, only a brief expression is enough249,250. This 
reveals the complexity of this therapy and the difficulty to find an effective protocol that 
can be translated into humans. Probably, the transient expression of Ags that could be 
provided by SV40 vectors may be enough to induce AST. To validate our hypotheses 
we expressed the selected self-Ag from the plasmid form to resemble what others did, 
but in the SV40 vector background.  
As a model of T1DM we have used the RIPB7.1 mice, since this model provides more 
flexibility and consistency at the time of inducing the hyperglycemia123,220,253,254. 
Furthermore, what makes also this model very interesting is, as we have shown here, 
the use of human insulin to induce the development of the hyperglycemia. The degree 
of homology between the human and mouse preproinsulin II genes is very high, and 
then, this was reasonably expected. This circumstance allowed us to use the human 
version in our vectors, giving us the chance to validate our AST approach with the 
same construct that would be used in future clinic trials. However, these mice develop 
a strong immune attack that could cover the real effect of the AST therapy. For this 
reason, small decreases in the percentage of mice that develop hyperglycemia could 
mean a great therapeutic benefit. 
Two different insulin variants have been considered for the AST: preproinsulin and 
proinsulin147,152,255,256. The difference between these variants is the presence of the 
signal peptide in the preproinsulin, which determines targeting the Ag to the ER, to be 
secreted. Probably, its secretion facilitates the presentation of insulin by the APCs 
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through the MHC II, previous its phagocytosis. Align with our hypotheses was the first 
positive outcome, to observe that insulin expressed in the SV40 background did not 
induced EAD in the RIPB7.1 mouse model. This was probably due to a lower 
expression levels of insulin, compared to the insulin-expressing plasmid used to induce 
EAD. This is consistent with a previous publication where a low Ag dose does not 
trigger immunogenicity but tolerance257. This may prelude that SV40 are safe, since a 
high Ag expression could trigger the activation of the immune system aggravating the 
situation of the patient. T1DM patients can present a susceptible state similar to the 
RIPB7.1, which only develop EAD after the administration of the high insulin 
expression plasmid and a ten times reduction of DNA avoids the development of EAD 
122,258.  
As it was shown by using other backbone plasmids149, insulin expressed in the 
background of SV40 can also induce AST, when administered by the intramuscular 
route. In fact, we resembled others results also in the way that we decided to express 
insulin, as preproinsulin or proinsulin, corroborating that the expression of proinsulin 
was more effective than preproinsulin to induce AST, following this procedure. It was 
unfortunate that the results were not equally positive when both Ags were delivered to 
the liver, in a try to harness its great tolerogenic potential 172,173,259. We could not 
analyze whether the Ags were being expressed properly in vivo, but a plausible reason 
about the fail to induce AST could be the capture of our insulin expressing plasmids by 
APCs and for some reason presented them under some pro-inflammatory environment 
252,260, because when we avoided the expression of the Ags in the hematopoietic cells 
by adding the micro-RNA targeting sequence miRT-142·3p, our vectors efficiently 
induced AST, via liver administration. Our results are consistent with previous results 
that also showed the used of the miRT-142·3p to induce AST 261, and others that 
described that a low Ag expression in hepatocytes or liver endothelial cells can induce 
an anti-inflammatory environment promoting tolerance 262–264. 
Here we show that genes carried by SV40 vectors can be efficiently expressed in liver, 
without inducing cytotoxicity, and more importantly, without inducing immunogenicity 
against the vector particles. Contrary to what happens with other viral vectors, these 
results mean that SV40 vector particles could be administered repeatedly, without 
detrimental circumstances neither for the patient or the therapeutic treatment. Equally 
relevant is that we show for the first time that self-Ags delivered and expressed in the 
background of SV40 are not able to initiate an autoimmune process, and that when the 
SV40 vector background is customized with sequences that target the expression to 
particular cells different from hematopoietic cells, AST is efficiently induced by upon 
liver administration. Now the challenge is to obtain proof of principle of SV40-
52 
 
expressing insulin vectors as a treatment for EAD in the RIPB7.1 mouse model.  These 
results, together with the availability of SuperVero packaging cells, that make possible 
the use of SV40 vectors in the clinic, we may predict that SV40 vector particles will 
make their niche in the gene therapy field.  
 
 
2. LRH1 as a novel target to treat T1DM: Analysis of the effect of LRH1 agonist 
BL001 in the innate immune system and screening for a second generation of 
LRH1 agonists 
 
For the development of a successful T1DM therapy, the balance between regulatory 
and self-reactive effector T cells should be reestablished as well as the β cell mass 
should be regenerated. Thus, identifying new targets that could combine both effects is 
necessary to design innovative drug-therapies. Here we propose LRH1 as a target for 
new T1DM pharmaceutical therapies.  The overexpression of LRH1 protects islets from 
cytokines and streptozotocin-induced apoptosis, revealing the protective role of this 
factor213. This nuclear receptor can be activated by ligands, which allows a 
pharmacological treatment for its activation. Remarkably, endogenous and newly 
synthesized LRH1 agonists have been deciphered as anti-diabetic drugs 218,220,265. Our 
previous data document that the administration of the LRH1 agonist BL001 reduces the 
incidence of hyperglycemia in different T1DM mouse models, preserving the β cell 
mass and inducing an anti-inflammatory environment 220. Hence, this compound primes 
macrophages towards the immunosuppressive and tissue remodeling M2 phenotype 
resulting in an increased IL-10 expression and inducing the expansion of Tregs 220, 
which are essential in maintaining the self-immune tolerance 266. Even in the presence 
of the strong pro-inflammatory LPS, BL001 is able to modulate the phenotype of these 
cells maintaining the expression of the anti-inflammatory cytokine IL-10, demonstrating 
its capacity to modulate the immune system 220. Supporting the action of BL001 as an 
agonist of LRH1, BL001-treated LRH1-silenced primary macrophages cannot increase 
the secretion of this cytokine. Remarkably, the benefits of this compound are not only 
restricted to the immune system. BL001 can also increase the dual hormone 
glucagon/insulin cells in immunized mice by reducing the α cell markers, suggesting 
the transdifferentiation of α cells into β cells in an attempt to compensate the loss of β 
cell mass without a significant effect on cell proliferation 220. Probably, Tregs and M2 
macrophages contribute to this α-to-β cell trans-differentiation, considering these 
subsets of cells key players in tissue remodeling in muscle, bone and vasculature, 
promoting cell differentiation and expansion 267–270.  
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However, a drawback of BL001 for its use in the clinic is that BL001 is a lipophilic 
molecule that does not comply with the four rules of Lipinski limiting its human 
applicability. Therefore, novel compounds that can act as agonists of LRH1 similar to 
BL001 but with hydrophilic properties that fulfil the Lipinski rules need to be identified. 
For being able to analyze these compounds, we have generated a new and quick 
method to screen and test novel LRH1 agonists. This assay is based on HepG2 cell 
line stably transduced with two fluorescence reporter transgenes: one of them 
regulated by activated LRH1 (using SHP promoter) and the other one with constitutive 
expression (using EF1α promoter). The analysis of the fluorescent proteins is 
performed by flow cytometry that allows the combination of different fluorescence 
signals at the same time, being able to analyze simultaneously different promoters 
(SHP and EF1α). The selection of compounds was based on their capacity to activate 
the endogenous LRH1 expressed in HepG2 cells, which can mimic the in vivo situation, 
where no overexpression of LRH-1 can be induced. The use of this platform facilitates 
the screening of new LRH1 agonists, being the only limitation the time to detect the 
fluorescent proteins, which we have demonstrated is optimal at 72 hours post-
treatment. Thus, considering the “unlimited” resource of a cell line, numerous 
compounds can be analyzed at the same time with a low cost and in a simple manner. 
Moreover, unlike previous reporter assay analysis, generally using transient 
transfections 233,271, the use of a stable cell line can produce more reproducible results, 
allowing the comparison between the different compounds tested. The validation of the 
SHP/EF1α HepG2 cells using BL001 determined the basal fluorescence level to select 
novel LRH1 agonists. Interestingly, overexpression of LRH1 itself do not reach the 
same fluorescence intensity than after BL001 treatment. A possible reason for this can 
be that the natural ligands of LRH1 present in the cells, the phospholipids, cannot 
increase the activity of this transcription factor as strong as BL001. Using this 
screening platform the novel LRH1 hydrophilic agonists have been compared to 
BL001, revealing two novel compounds with an improved activity: BL002 and BL003.  
Besides the validation of their function, in our case as agonists of LRH1, for the 
development of new pharmaceutical compounds is important to study their potential 
toxicity, which is one of the most important causes of drug rejection in later stages of 
drug development. The toxicology studies that we have performed indicate that both, 
BL002 and BL003, are non-toxic at the doses required for the activation of LRH1, 
however BL002 at high doses, but not BL003, can impact negatively on cell growth. 
This difference between these two compounds could be due to the activation potency 
of BL002, which at 25µM not only increases the GFP fluorescence, but also increases 
the DsRed levels. These data suggest that high concentration of BL002 could activate 
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unspecific promoters or even induce toxicity, although further experiments are needed 
to analyze the specificity of this compound.  
Previous reports have suggested a role of LRH1 in some tumours 272, however, the 
absence of increased proliferation after treatment with the BL compounds, together 
with our previous studies using BL001 both in vitro and in vivo 220 have questioned the 
tumorigenesis risk. However, further experiments are needed to corroborate the safety 
of the novel BL compounds. Based in our in vitro results with these compounds, we 
expect that the in vivo administration of BL002 and BL003 will act similarly to BL001, 
which after 6 months of diary administration does not induce tumour development 220. 
Similar to the protection against cytokines and streptozotocin-induced apoptosis 
conferred by the overexpression of  LRH1 213 as well as by the activation of LRH1 by 
BL001 220, the novel BL compounds protect mouse islets from cytokines-induced 
apoptosis. Remarkably, when compared to BL001, 100 times lower doses of BL002 
and BL003 were enough to protect mouse islets from apoptosis, demonstrating their 
stronger effect. In the case of BL002, the lowest doses correlate the highest protection, 
being abrogated when the doses are increased, which are toxic for the cells. Probably, 
the reduction of cell death that we have observed at 25µM (but not at 12µM) is an 
artefact due to few cells surviving after the treatment. This is consistent with the BL002 
basal cell death of islets observed at 12µM, which can even increase the cell death. 
Nevertheless this hypothesis needs to be corroborated. Interestingly, although in the 
screening platform we only detected the LRH1 activation at high concentrations (with 
apparently no effect with lower than 6 µM BL002), the highest protection against 
apoptosis was observed at lower values. This demonstrates the necessity of testing the 
compounds in vivo, since the concentration to identify the agonists in the stable cell line 
could be much higher than the concentration beneficial in a physiological scenario such 
as islets. Probably, it is not required a high activation of LRH1 in vivo to induce 
protection. However, further experiments are necessary to corroborate the in vivo 
validation and the mechanism of action. As a counterpart, BL003, which previously has 
been shown to be less toxic, protects mouse islets at all the concentrations tested and 
can even improve the survival of mouse islets reducing the basal cell death. Despite 
the requirement of further analysis in vivo, considering the encouraging results 
obtained with BL001, these novel compounds show an strong potential for their use in 
T1DM treatment. The absence of either toxicity or proliferation induction, as well as the 
wide range of concentrations able to protect pancreatic islet from apoptosis designate 
BL003 as a good candidate for a future T1DM therapy.  
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Here, a screening platform is presented with the objective of testing novel LRH1 
agonists. As a result, an improved generation compounds of BL001 is presented 
emphasizing two of them, BL002 and BL003. These compounds can reduce the doses 
necessary for the protection of β cells by an enhanced binding affinity to LRH1 than 
BL001. Although in vivo experiments need to be performed, these results can augur 
their application as T1DM treatment. 
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VII. CONCLUSIONS 
 
 
1. SV40 vectors as a tool to induce AST in a T1DM mouse model 
 
1. The establishment of the packaging cell line SuperVero in combination with the 
absence of an immune response to vector particles will allow the safe use of 
SV40-derived vectors in the clinic 
2. The use of human preproinsulin to induce EAD in the transgenic mouse model 
RIPB7.1 increases the translational value of this model 
3. Intramuscular expression of self-antigens under the transcriptional control of 
SV40 early promoter induces immune tolerance to the self-antigen 
4. By preventing expression of self-antigens by hematopoietic cells, upon 
intravenous administration of self-antigen-expressing SV40 vectors, the 
induction of inflammation is avoided and instead the induction of antigen 
specific tolerance is improved 
 
2. LRH1 as a novel target to treat T1DM: Analysis of the effect of LRH1 agonist 
BL001 in the innate immune system and screening for a second generation 
 
1. BL001 is capable of inducing IL10 production in peritoneal macrophages but not 
TGF 
2. Silencing of LRH1, prevents induction of IL10 by BL001, validating the 
specificity of the BL001/LRH1 signaling pathway. 
3. The generation of a cell-based screening platform to identify compounds that 
induces the SHP promoter is a valuable tool for the development drugs with 
potential anti-inflammatory effect 
4. The preliminary in vitro profiles of the compounds BL002 and BL003 in terms of 
toxicology and islet protection, prelude their therapeutic benefit at the moment 
of being tested in the experimental autoimmune diabetes preclinical model 
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